Primaquine Phosphate Tablets Trader

1. Product Introduction

Primaquine is an 8-aminoquinoline antimalarial medicine used for the radical cure of Plasmodium vivax and P. ovale malaria by targeting dormant liver-stage parasites (hypnozoites), alongside an appropriate blood-stage antimalarial. It may also be used in selected transmission-blocking or prevention regimens under applicable national guidelines. Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter in the supplied product information; current product authorizations and manufacturing capabilities should be confirmed before commercial commitments.

2. Product Specifications and Variants

Label clarification: Strengths are expressed as primaquine base equivalents, not the weight of primaquine phosphate salt. Excipients q.s.; the BP 7.5 mg formulation lists red iron oxide. Packaging, shelf life, regulatory approvals and batch specifications require confirmation.

3. Manufacturing Primaquine Tablets

Manufacturer — Healthy Life Pharma Pvt. Ltd.: The supplied portfolio identifies film-coated and sugar-coated versions. These coatings can help mask the bitter taste of primaquine. Low-strength formulations require validated weighing, mixing, compression and content-uniformity controls. Specific coating technology, manufacturing site certification and production capacity should be verified against current records.

Exporter — Healthy Inc: Procurement for malaria-control programs may require destination-specific registration, tender documentation, labeling, packaging and stability evidence. Bulk supply capabilities and shipping arrangements are subject to confirmation.

4. Quality Assurance

Quality controls should follow the approved pharmacopoeial monograph and registered specifications, including identification and assay of primaquine phosphate, dosage-unit uniformity, dissolution or disintegration where applicable, related substances, and stability. Validated methods such as HPLC may be appropriate; actual test methods and acceptance limits must be confirmed from the product dossier. A 36-month shelf life should not be claimed without supporting stability studies.

5. Mechanism and Therapeutic Uses

Primaquine acts against tissue stages of malaria parasites, notably dormant liver forms of P. vivax and P. ovale, helping prevent relapse. It also has activity against malaria gametocytes in selected public-health regimens. It is not a stand-alone substitute for the appropriate blood-stage antimalarial in acute malaria treatment.

Critical safety requirement: Quantitative or otherwise guideline-appropriate G6PD testing before radical-cure treatment is essential because primaquine can cause severe hemolysis in people with G6PD deficiency.

6. Export and Regulatory Support

For procurement and export, confirm the destination country's registration requirements, authorized strength and dosage form, GMP documentation, certificates of analysis, stability data, labeling and relevant export documents. Availability of CTD/ACTD dossiers, COPP, free-sale certificates, specific shipping terms and WHO-GMP credentials must be verified with the manufacturer/exporter.

7. Frequently Asked Questions

What strengths are listed?

Primaquine base equivalents of 2.5 mg, 7.5 mg and 15 mg, in the specific IP/BP and coating variants shown above.

Is G6PD testing needed?

Yes. G6PD status must be assessed before primaquine regimens that carry a hemolysis risk; the prescriber selects the regimen based on results and local guidance.

Can primaquine be taken during pregnancy?

Primaquine is generally contraindicated during pregnancy because fetal G6PD status cannot reliably be established. Follow current prescribing guidance.

Is primaquine the same as chloroquine?

No. They act at different stages of malaria infection and may be used together in some approved regimens.

Is primaquine always given after chloroquine?

No. The companion blood-stage antimalarial and timing depend on malaria species, local resistance patterns, treatment guidelines and clinical assessment; chloroquine is not universally appropriate.

8. Dosage and Administration

Dosage depends on malaria species, treatment purpose, patient age and weight, G6PD status and country-specific recommendations. Do not use a universal dosing schedule. Take only as prescribed; administration with food may reduce gastrointestinal upset. A clinician must select any companion antimalarial and assess relevant contraindications.

9. Side Effects and Precautions

• Hemolytic anemia: Potentially severe in G6PD deficiency; seek urgent assessment for dark urine, pallor, jaundice, unusual fatigue or breathlessness.
• Methemoglobinemia: May cause cyanosis or shortness of breath, particularly in susceptible individuals.
• Other effects: Nausea, abdominal discomfort, headache and dizziness may occur.
• Pregnancy and breastfeeding: Avoid in pregnancy; breastfeeding use requires assessment of infant G6PD status and current labeling.
• Interactions: Review other medicines that can cause hemolysis, methemoglobinemia or relevant cardiac risks.

Additional caution: Primaquine should not be presented as universally safe for all patients. G6PD screening, pregnancy status, other medicines and the applicable national malaria protocol are essential to treatment selection.

10. Storage Instructions

Store in the original, properly labeled packaging according to the approved product-specific storage conditions. Protect from moisture and light as directed. Keep out of reach of children. Confirm the actual temperature limit and shelf life from the approved label and stability data.